| アブストラクト | Background/Objectives: Guidelines for obstructive hypertrophic cardiomyopathy (HCM) recommend treatment with disopyramide as an add-on to beta-blockers or calcium-channel blockers when symptoms persist. Data pertaining to effective disopyramide use in practice beyond single-center experience are very limited. This study aimed to quantify disopyramide use in patients with obstructive HCM in England, France and Germany, before the availability of cardiac myosin inhibitors. Methods: This retrospective study used nationally representative databases from England (Clinical Practice Research Datalink and Hospital Episode Statistics, 2010-2019), France (National Healthcare Data System, 2012-2019) and Germany (German statutory health insurance, 2011-2019). Adults (18+) with obstructive HCM were included, based on diagnostic codes for obstructive HCM or any HCM with septal reduction therapy. Disopyramide usage was defined as >/=1 prescription for a patient in a calendar year. Results: Overall, 3730, 6823 and 1141 patients diagnosed with obstructive HCM were identified in the English, French and German databases, respectively. In England, disopyramide use ranged from 4.7% to 5.6% per year with use generally stable over time. The equivalent usage for France was 1.7% to 2.6% per year. As expected, no recorded reimbursed use was reported in Germany during the study period. Conclusions: Disopyramide use is very low in patients with obstructive HCM, possibly due to treatment-related issues, availability or lack of reimbursement. These barriers may drive the uptake of alternative guideline recommended therapies for obstructive HCM treatment. |
|---|
| ジャーナル名 | Journal of clinical medicine |
|---|
| Pubmed追加日 | 2026/6/12 |
|---|
| 投稿者 | Charron, Philippe; Osman, Faizel; Trochu, Jean-Noel; Zema, Carla; Hurst, Michael; Sandler, Belinda; Cotte, Francois-Emery; Lemmer, Teresa; Esteban, Maite Tome |
|---|
| 組織名 | Department of Cardiology & Department of Genetics, Hopital Universitaire;Pitie-Salpetriere, IHU-ICAN, INSERM 1166, AP-HP, Sorbonne Universite, 75013;Paris, France.;Institute of Cardio-Metabolic Medicine, University Hospitals Coventry and;Warwickshire NHS Trust, Coventry CV2 2DX, UK.;Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.;L'institut du Thorax, Hopital Universitaire, Nantes Universite, INSERM, Centre;National de Recherche Scientifique, 44035 Nantes, France.;Bristol Myers Squibb, Princeton, NJ 08543, USA.;Bristol Myers Squibb, Uxbridge UB8 1DH, UK.;Bristol Myers Squibb, 92506 Rueil-Malmaison, France.;Department of Cardiology, St George's NHS Foundation Trust & St George's;University of London, London SW17 0QT, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42279095/ |
|---|
